Biohaven showed yesterday that not all launches by small companies end in disaster. And impressive second-quarter sales of its oral migraine therapy, Nurtec ODT, will only have increased speculation that the group could be a takeover target.
One company that might do well to consider buying Biohaven is Glaxosmithkline, which needs some fresh blood to placate the activist investor Elliott Management.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,